Abstract | OBJECTIVES: METHODS: RESULTS: Ascitic fluid accumulation (2.47, 2.65, 2.88, and 5.90 mL, respectively) and in ascitic VEGF levels were significantly reduced in the 3 treatment groups compared to the control group (170.83, 229.16, 267, and 1625 pg/mL, respectively). However, complete tumor suppression was more prominent in the paclitaxel group, and VEGF mRNA expression was more strongly inhibited in the albendazole group (P < .05). No synergistic effect of albendazole and paclitaxel was observed. CONCLUSION:
|
Authors | Eun-Kyoung Choi, Sang-Wun Kim, Eun-Ji Nam, Jiheum Paek, Ga-Won Yim, Myeong-Hwa Kang, Young-Tae Kim |
Journal | Reproductive sciences (Thousand Oaks, Calif.)
(Reprod Sci)
Vol. 18
Issue 8
Pg. 763-71
(Aug 2011)
ISSN: 1933-7205 [Electronic] United States |
PMID | 21421899
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- RNA, Messenger
- Tubulin Modulators
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- Albendazole
- Paclitaxel
|
Topics |
- Albendazole
(administration & dosage)
- Animals
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(pharmacology)
- Ascites
(metabolism)
- Female
- Mice
- Mice, Nude
- Ovarian Neoplasms
(drug therapy, genetics, metabolism)
- Paclitaxel
(administration & dosage)
- RNA, Messenger
(biosynthesis, genetics)
- Reverse Transcriptase Polymerase Chain Reaction
- Tubulin Modulators
(administration & dosage)
- Vascular Endothelial Growth Factor A
(biosynthesis, genetics)
|